{"id":52140,"date":"2022-12-19T19:02:43","date_gmt":"2022-12-19T18:02:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/2022-in-vitro-diagnostics-ivd-market-in-malaysia-singapore-and-indonesia-featuring-caris-life-sciences-cephei-ctk-biotech-danaher-and-dexcom-among-others-researchandmarkets-com\/"},"modified":"2022-12-19T19:02:43","modified_gmt":"2022-12-19T18:02:43","slug":"2022-in-vitro-diagnostics-ivd-market-in-malaysia-singapore-and-indonesia-featuring-caris-life-sciences-cephei-ctk-biotech-danaher-and-dexcom-among-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/2022-in-vitro-diagnostics-ivd-market-in-malaysia-singapore-and-indonesia-featuring-caris-life-sciences-cephei-ctk-biotech-danaher-and-dexcom-among-others-researchandmarkets-com\/","title":{"rendered":"2022 In Vitro Diagnostics (IVD) Market in Malaysia, Singapore and Indonesia: Featuring Caris Life Sciences, Cephei, CTK Biotech, Danaher and Dexcom Among Others – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe Asia Pacific (APAC) region is a fast-growing in vitro diagnostics (IVD) market, which is witnessing increasing focus by leading global players in the market. Southeast Asia has been identified as one of the key regions in APAC region offering significant opportunities for IVD companies.\n<\/p>\n

\nThis report focuses on three IVD markets in Southeast Asia: Malaysia, Indonesia, and Singapore. These three countries together represent a fast-growing geographic region offering significant opportunity for IVD companies. The total population of these three countries is over 310 million, which is close to the population in the United States.\n<\/p>\n

\nAmong these three countries, Singapore has established world class healthcare service capabilities in terms of infrastructure as well as skilled manpower. Though the population is less than 6 million, the Singapore market is attractive for IVD companies and it has become a medical tourism hub in the region.\n<\/p>\n

\nIndonesia, on the other hand, is a country with a huge population of about 275 million people. The country is taking significant steps to improve its healthcare infrastructure, which is offering considerable opportunities for IVD companies. The Malaysian market, with a population of about 32 million falls in between these two countries, both in terms of healthcare service capabilities and growth potentials.\n<\/p>\n

\nIn Vitro Diagnostics (IVD) in Malaysia, Singapore, and Indonesia, 2022 covers the following segments:<\/strong>\n<\/p>\n